The melatonin market is estimated to be valued at USD 635.1 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031.  Melatonin is a hormone produced by the pineal gland located in the brain. It helps regulate the wake-sleep cycle and is involved in the circadian rhythm. As the pineal gland produces more melatonin during the night, it makes us feel sleepy and tired. Melatonin levels start increasing in the evening around 8-9 pm as it gets darker, and peak during the middle of the night between 2-3 am. Melatonin supplements are used to treat jet lag and insomnia, and to promote better sleep. The global melatonin market has been growing in recent years due to increasing demand for natural sleep aids.

 Market Dynamics:

The global melatonin market is driven by factors such as increasing stress levels and sleep disorders among people, growing health consciousness, and rising geriatric population vulnerable to sleep problems. According to the National Sleep Foundation, over 50 million Americans suffer from over 70 different types of sleep disorders. Long and irregular working hours has also disrupted the body's natural circadian rhythm, boosting demand for melatonin supplements. However, lack of awareness regarding melatonin dosage and side effects in some countries, and easy availability of alternative sleep medications could restrain market growth. The shift towards natural ingredients-based products and entry of new players developing innovative delivery forms presents promising opportunities in this space.

 Key Features of the Study:

• This report provides in-depth analysis of the global melatonin market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global melatonin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Natrol, Pharmative, Nature’s Bounty, Jameison, Rexall Sundown, GNC, Xiu Zheng, Finex OY, Church & Dwight, By-Health, Pfizer, Solgar, Biotics Research, New Food, Neurim Pharmaceuticals Ltd., Pulse Pharmaceuticals Pvt.Ltd., Schiff Nutrition International Inc., Fidia Farmaceutici S.P.A, Joshi Agrochem Pharma, and Neurim Pharmaceuticals pvt.Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global melatonin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Detailed Segmentation-

• By Source:
  • Plants
  • Animals
  • Bacteria
  • Others (fungi, etc.)
• By Type:
  • Natural Melatonin
  • Synthetic Melatonin
• By End User:
  • Pharmaceuticals
  • Food & Beverage
  • Medical & Healthcare
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Natrol
  • Pharmative
  • Nature’s Bounty
  • Jameison
  • Rexall Sundown
  • GNC
  • Xiu Zheng
  • Finex OY
  • Church & Dwight
  • By-Health
  • Pfizer
  • Solgar
  • Biotics Research
  • New Food
  • Neurim Pharmaceuticals Ltd.
  • Pulse Pharmaceuticals Pvt.Ltd.
  • Schiff Nutrition International Inc.
  • Fidia Farmaceutici S.P.A
  • Joshi Agrochem Pharma
  • Neurim Pharmaceuticals pvt.Ltd.